MYnd Analytics Expands Its Business With Opening of First MYnd Analytics Center in Southern California

Print
| Source: MYnd Analytics, Inc.

LAS VEGAS, March 09, 2016 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (OTCQB:CNSO) has expanded its business through the opening of its first MYnd Analytics Center in Laguna Hills, CA. This dedicated facility will provide EEG testing in a relaxed, customer-friendly environment. The EEGs are used with MYnd Analytics’ PEER Online, a platform that provides doctors with objective information about medication response based on their patients’ unique brainwave patterns.

George Carpenter, President and CEO of MYnd Analytics, said, “The MYnd Analytics Center provides doctors in Southern California a convenient turnkey EEG site for their patients, and offers patients an optimal EEG testing process that makes getting a PEER Report easier.”

Physicians and patients interested in learning more about the MYnd Analytics Center are encouraged to contact Kerry Polich at 1-888-545-2677. The announcement of the opening was made as part of the Company’s presentation at the National Council for Behavioral Health conference in Las Vegas, NV.

About MYnd Analytics, Inc.

Mynd Analytics, Inc. (www.myndanalytics.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG).  Based on the Company’s original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER Registry. The objective of PEER Online is to avoid trial and error pharmacotherapy, which is the dominant approach for treatment resistant patients. To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

 

Contact:

Media
Laura Radocaj
DGI
(212) 825-3210